Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Identifieur interne : 000649 ( PascalFrancis/Checkpoint ); précédent : 000648; suivant : 000650Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Auteurs : Robert A. Hauser [États-Unis] ; Aaron L. Ellenbogen [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Ann Hsu [États-Unis] ; Martin J. O'Connell [États-Unis] ; Nishit B. Modi [États-Unis] ; Hsuan-Ming Yao [États-Unis] ; Sherron H. Kell [États-Unis] ; Suneel K. Gupta [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended-release formulation of carbidopa-levodopa, with an immediate-release carbidopa-levodopa formulation in advanced Parkinson's disease. We performed an open-label crossover study in 27 subjects with advanced Parkinson's disease experiencing motor fluctuations on levodopa therapy. Subjects were randomized 1:1 to 8 days' treatment with either immediate-release carbidopa-levodopa followed by IPX066 or IPX066 followed by immediate-release carbidopa-levodopa. Pharmacokinetic and motor assessments were undertaken on day 1 for 8 hours (following a single dose) and on day 8 for 12 hours (during multiple-dose administration). Following a single dose of IPX066 or immediate-release carbidopa-levodopa, plasma levodopa concentrations increased at a similarly rapid rate and were sustained above 50% of peak concentration for 4 hours with IPX066 versus 1.4 hours with immediate-release carbidopa-levodopa (P <.0001). Multiple-dose data showed IPX066 substantially reduced variability in plasma levodopa concentrations despite a lower dosing frequency (mean, 3.5 vs 5.4 administrations per day). In addition, total levodopa exposure during IPX066 treatment was approximately 87% higher, whereas the increase in levodopa Cmax was approximately 30% compared with immediate-release carbidopa-levodopa. Both products were well tolerated. IPX066 provided more sustained plasma levodopa concentrations than immediate-release carbidopa-levodopa. Larger, longer-term, well-controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:11-0481763Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1><s2>Tampa, Florida</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Michigan Institute for Neurological Disorders and Quest Research Institute</s1><s2>Farmington Hills, Michigan</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yao, Hsuan Ming" sort="Yao, Hsuan Ming" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0481763</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0481763 INIST</idno><idno type="RBID">Pascal:11-0481763</idno><idno type="wicri:Area/PascalFrancis/Corpus">000371</idno><idno type="wicri:Area/PascalFrancis/Curation">002947</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000649</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1><s2>Tampa, Florida</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Michigan Institute for Neurological Disorders and Quest Research Institute</s1><s2>Farmington Hills, Michigan</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yao, Hsuan Ming" sort="Yao, Hsuan Ming" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Comparative study</term><term>Fluctuations</term><term>Formulation</term><term>Levodopa</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Pharmacokinetics</term><term>Release</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Etude comparative</term><term>Lévodopa</term><term>Formulation</term><term>Stade avancé</term><term>Libération</term><term>Pharmacocinétique</term><term>Fluctuation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended-release formulation of carbidopa-levodopa, with an immediate-release carbidopa-levodopa formulation in advanced Parkinson's disease. We performed an open-label crossover study in 27 subjects with advanced Parkinson's disease experiencing motor fluctuations on levodopa therapy. Subjects were randomized 1:1 to 8 days' treatment with either immediate-release carbidopa-levodopa followed by IPX066 or IPX066 followed by immediate-release carbidopa-levodopa. Pharmacokinetic and motor assessments were undertaken on day 1 for 8 hours (following a single dose) and on day 8 for 12 hours (during multiple-dose administration). Following a single dose of IPX066 or immediate-release carbidopa-levodopa, plasma levodopa concentrations increased at a similarly rapid rate and were sustained above 50% of peak concentration for 4 hours with IPX066 versus 1.4 hours with immediate-release carbidopa-levodopa (P <.0001). Multiple-dose data showed IPX066 substantially reduced variability in plasma levodopa concentrations despite a lower dosing frequency (mean, 3.5 vs 5.4 administrations per day). In addition, total levodopa exposure during IPX066 treatment was approximately 87% higher, whereas the increase in levodopa C<sub>max</sub> was approximately 30% compared with immediate-release carbidopa-levodopa. Both products were well tolerated. IPX066 provided more sustained plasma levodopa concentrations than immediate-release carbidopa-levodopa. Larger, longer-term, well-controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>26</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease</s1></fA08><fA11 i1="01" i2="1"><s1>HAUSER (Robert A.)</s1></fA11><fA11 i1="02" i2="1"><s1>ELLENBOGEN (Aaron L.)</s1></fA11><fA11 i1="03" i2="1"><s1>METMAN (Leo Verhagen)</s1></fA11><fA11 i1="04" i2="1"><s1>HSU (Ann)</s1></fA11><fA11 i1="05" i2="1"><s1>O'CONNELL (Martin J.)</s1></fA11><fA11 i1="06" i2="1"><s1>MODI (Nishit B.)</s1></fA11><fA11 i1="07" i2="1"><s1>YAO (Hsuan-Ming)</s1></fA11><fA11 i1="08" i2="1"><s1>KELL (Sherron H.)</s1></fA11><fA11 i1="09" i2="1"><s1>GUPTA (Suneel K.)</s1></fA11><fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1><s2>Tampa, Florida</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Michigan Institute for Neurological Disorders and Quest Research Institute</s1><s2>Farmington Hills, Michigan</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Impax Pharmaceuticals</s1><s2>Hayward, California</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></fA14><fA20><s1>2246-2252</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000505557630170</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>20 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0481763</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended-release formulation of carbidopa-levodopa, with an immediate-release carbidopa-levodopa formulation in advanced Parkinson's disease. We performed an open-label crossover study in 27 subjects with advanced Parkinson's disease experiencing motor fluctuations on levodopa therapy. Subjects were randomized 1:1 to 8 days' treatment with either immediate-release carbidopa-levodopa followed by IPX066 or IPX066 followed by immediate-release carbidopa-levodopa. Pharmacokinetic and motor assessments were undertaken on day 1 for 8 hours (following a single dose) and on day 8 for 12 hours (during multiple-dose administration). Following a single dose of IPX066 or immediate-release carbidopa-levodopa, plasma levodopa concentrations increased at a similarly rapid rate and were sustained above 50% of peak concentration for 4 hours with IPX066 versus 1.4 hours with immediate-release carbidopa-levodopa (P <.0001). Multiple-dose data showed IPX066 substantially reduced variability in plasma levodopa concentrations despite a lower dosing frequency (mean, 3.5 vs 5.4 administrations per day). In addition, total levodopa exposure during IPX066 treatment was approximately 87% higher, whereas the increase in levodopa C<sub>max</sub> was approximately 30% compared with immediate-release carbidopa-levodopa. Both products were well tolerated. IPX066 provided more sustained plasma levodopa concentrations than immediate-release carbidopa-levodopa. Larger, longer-term, well-controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Etude comparative</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Comparative study</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Formulation</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Formulation</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Formulación</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Stade avancé</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Advanced stage</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Estadio avanzado</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Libération</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Release</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Liberación</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Pharmacocinétique</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Pharmacokinetics</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Farmacocinética</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Fluctuation</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Fluctuations</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Fluctuación</s0><s5>15</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>332</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Illinois</li><li>Michigan</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></region><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name><name sortKey="Yao, Hsuan Ming" sort="Yao, Hsuan Ming" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:11-0481763
|texte= Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |